China 
Africa 
Explore chapters and articles related to this topic
Pleural disease induced by drugs
Published in Philippe Camus, Edward C Rosenow, Drug-induced and Iatrogenic Respiratory Disease, 2010
Bleomycin, an antitumour antimicrobial agent, is used in the treatment of head and neck cancers, testicular carcinoma, and Hodgkin’s and non-Hodgkin’s lymphoma. Pleuropulmonary adverse effects occur in 6–10 per cent of patients with a mortality rate just under 2 per cent. The most common and devastating form of bleomycin-induced pulmonary disease is the development of interstitial pneumonitis and acute respiratory distress syndrome (ARDS) that may progress to pulmonary and pleural fibrosis enhanced by the use of high concentrations of oxygen, radiation therapy or other chemotherapeutic agents. Both pleural and lung toxicity are age- and dose-related: it is more common in patients older than 70 years and in those who receive a cumulative dose above 400 mg/m2. Pleural effusions have been reported in a few patients with bleomycin lung toxicity.11 The combination of drug cessation and corticosteroid therapy may result in resolution of the effusions and pneumonitis.
Potential Use of Bioactive Compounds from Waste in the pharmaceutical Industry
Published in Quan V. Vuong, Utilisation of Bioactive Compounds from Agricultural and Food Waste, 2017
Date is the most popular fruit in the Middle East and its by-products can be used as substrate for producing value-added products in the pharmaceutical industry. Abou-Zeid et al. (1993) utilized date constituents as a nutrient for the production of oxytetracycline, an antibiotic active on Gram-positive and Gram-negative bacteria produced by different species of Streptomyces. Bleomycin is a family of glycopeptide- derived antibiotics having strong antitumor activity and employed for the treatment of several malignancies, including non-Hodgkin’s lymphoma, squamous cell carcinoma and testicular tumors (Aras and Dilsizian 2008, Evens et al. 2008). Radwan et al. (2010) used a date syrup for the production of bleomycin through Streptomyces mobaraensis.
Radio-Electro-Chemotherapy of Cancer: New Perspectives for Cancer Treatment
Published in Pandit B. Vidyasagar, Sagar S. Jagtap, Omprakash Yemul, Radiation in Medicine and Biology, 2017
Pratip Shil, Pandit B. Vidyasagar, Kaushala Prasad Mishra
Initial electrochemotherapy had been performed with anticancer drug bleomycin and cisplatin yielded excellent results. As a result, bleomycin has been used for clinical trials [36, 37, 38, 39–40]. Bleomycin was administered by intravenous injection, intratumoral or intraarterial [41, 42]. The application of the drug was mostly of the dose of 10–15 mg/m2 and the square (or rectangular) wave electric pulses with 100 μs duration and 1300 kV/cm field had been used [35, 36, 37, 38, 39, 40, 41–42]. In most cases, the electric pulses were applied 1–15 min after the intratumoral injection of bleomycin.
DNA damage and reticular stress in cytotoxicity and oncotic cell death of MCF-7 cells treated with fluopsin C
Published in Journal of Toxicology and Environmental Health, Part A, 2022
Luan Vitor Alves de Lima, Matheus Felipe da Silva, Virginia Marcia Concato, Débora Berbel Lirio Rondina, Thalita Alves Zanetti, Ingrid Felicidade, Lilian Areal Marques, Sandra Regina Lepri, Ane Stéfano Simionato, Galdino Andrade Filho, Giuliana Castello Coatti, Mário Sérgio Mantovani
As it is cytotoxic to MCF-7 cells, data demonstrated that fluopsin C exerted different modes of action that induced cell death, including (1) disruption of cell metabolism, (2) DNA damage, (3) cell cycle arrest in G1, (4) adverse MMP alterations, and (5) attenuation of the formation of new clones. Thus, fluopsin C displayed antitumor activity similar to other antibiotics, currently used in the clinic, such as anthracyclic and non-anthracyclic antibotics (Bolzán and Bianchi 2018; Gao et al. 2020; Lüpertz et al. 2010; Slingerland, Guchelaar, and Gelderblom 2012). For example, DXR as its mode of action enhances production of ROS resulting in DNA damage and arresting the cell cycle (Lüpertz et al. 2010), which is used in hematologic cancers and solid tumors (Slingerland, Guchelaar, and Gelderblom 2012), as well as bleomycin, used in cancers of the digestive tract, cervix lung, and esophagus (Gao et al. 2020), where the predominant main mode of action is a genotoxic effect (Bolzán and Bianchi 2018).
The Combined Effect of Aqueous Tulasi Extract and Electrical Pulses on the Viability of HeLa Cells
Published in IETE Journal of Research, 2022
Jeya Shree Thulasidas, Gowri Sree Varadarajan, Lakshya Mittal, Raji Sundararajan
To enhance its uptake, electrical pulses (EP) can be used. This new and revolutionary cancer treatment called Electrochemotherapy (ECT) has been introduced to overcome the disadvantages of existing cancer treatments. ECT has been gaining attention among various researchers over the last decades to treat various types of cancers [16]. ECT combines local administration of chemotherapeutic drugs followed by the application of EP to the tumor or site of previous tumor removal [17–19]. EP application following intravenous or intratumoral injection of chemotherapeutic drugs creates temporary pores on the cancer cell membrane which enables the higher uptake of drug to the cancer cell than would be achieved with the chemotherapy alone [20,21]. The ultimate consequence of ECT is increased uptake of drug into the cancer cells thereby enhancing the cancer cell death [22,23]. Numerous studies have demonstrated increased transportation of drugs such as bleomycin and cisplatin into cancer cells [24–27]. ECT can be also used in combination with surgery or radiation therapy for cutaneous and subcutaneous tumors. ECT used in combination with surgery helps to kill any residual cancer cells at the surgical site and to prevent tumor regrowth.
Paclitaxel and etoposide-loaded Poly (lactic-co-glycolic acid) microspheres fabricated by coaxial electrospraying for dual drug delivery
Published in Journal of Biomaterials Science, Polymer Edition, 2018
Mei Zhang, Yajun Tang, Zhenhua Zhu, He Zhao, Jihang Yao, Dahui Sun
Osteosarcoma (OS) is one malignant connective tissue tumor, the incidence of osteosarcoma takes the first position among the malignant tumor. Osteosarcoma is a common, high malignant degree and poor prognosis entity of the malignant osseous tumor. It’s spread to the lungs in a few months. The survival rate is only 5 to 20% after amputation 3 to 5 years. Local resection or resection of the tumor and chemotherapy may be used in the treatment of low grade osteosarcoma and peripheral sarcoma. If the tumor is highly malignant, preoperative chemotherapy plus amputation and postoperative chemotherapy should be adopted. The completion of the operation is not the end of the treatment, patients should adhere to the doctor's advice, insist on regular chemotherapy, in order to have a good prognosis. Significant progress have been made in the OS treatment in the preoperative chemotherapy with cisplatin (DDP), adriamycin (ADR), methotrexate-tetrahydrofolic acid (MTX-CF), bleomycin-cyclophosphamide-dactinomycin (BCD), ifosfamide (IFO) and cyclophosphamide (CTX), etc., and the distance-disease-free survival is 42–89% [1–3].